Zobrazeno 1 - 10
of 168
pro vyhledávání: '"Debu, Tripathy"'
Autor:
Denise M. Wolf, Jane Perlmutter, Judy C. Boughey, A. Jo Chien, Meredith Buxton, Gillian L. Hirst, Douglas Yee, Angela DeMichele, Andres Forero-Torres, Scott M. Berry, Erin D. Ellis, Anthony D. Elias, Julia Wulfkuhle, Michael Alvarado, Christina Yau, Stacy L. Moulder, Nola M. Hylton, Rita Nanda, Amy Wilson, Adam Asare, Debu Tripathy, Claudine Isaacs, Melissa Paoloni, Rosa I. Gallagher, Laura J. Esserman, Richard Schwab, W. Fraser Symmans, Cheryl Ewing, Laura J. van't Veer, Jeffrey B. Matthews, Teresa Helsten, Julia L. Clennell, Barbara Haley, Emanuel F. Petricoin, Katherine Steeg, Smita Asare, Ashish Sanil, Rachel L. Yung, Erin P. Crane, Erin Roesch, Hyo S. Han, Ruby Singhrao, Michelle E. Melisko, Hope S. Rugo, Kathy S. Albain, Donald A. Berry, Anne M. Wallace, Julie E. Lang, Amy S. Clark, Kathleen Kemmer, Lamorna Brown-Swigart
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
Nature communications, vol 12, iss 1
Nature Communications
Nature communications, vol 12, iss 1
Nature Communications
HER2-targeted therapy dramatically improves outcomes in early breast cancer. Here we report the results of two HER2-targeted combinations in the neoadjuvant I-SPY2 phase 2 adaptive platform trial for early breast cancer at high risk of recurrence: ad
Autor:
Sonal Shad, William Fraser Symmans, Debu Tripathy, Lamorna Brown-Swigart, LJ Esserman, Jane Perlmutter, V. Valero, Rebekah Gould, Gregor Krings, Judy C. Boughey, Jodi M. Carter, M. van der Noordaa, Gillian L. Hirst, L.J. van 't Veer, Christina Yau, Douglas Yee, Lajos Pusztai, Tufia C. Haddad, Kathy S. Albain, Molly Klein, Lili Du, MC Liu, Rita Nanda, Claudine Isaacs, Richard Schwab, Amy Jo Chien, Donald A. Berry, Rachel M. Layman, AM DeMichele, Isabelle Bedrosian, Sara J. Venters, Nola M. Hylton
Publikováno v:
Annals of Oncology. 32:642-651
BACKGROUND We proposed that a test for sensitivity to the adjuvant endocrine therapy component of treatment for patients with stage II-III breast cancer (SET2,3) should measure transcription related to estrogen and progesterone receptors (SETER/PR in
Autor:
Joanne L. Blum, Meghan Sri Karuturi, Timothy J. Pluard, Erin Jepsen, Yao Wang, Thomas Stanton, Jay Anderson, Joseph C. Cappelleri, Adnan Garrett, Debu Tripathy, Faith Beery, Kenneth Manning
Publikováno v:
Cancer Research. 81:PS7-19
Background: POLARIS is an ongoing, prospective, real world, noninterventional study in patients (pts) with HR+/HER2– ABC receiving PAL. This interim report describes real-world PAL use in preMeno pts. Methods: POLARIS has a targeted enrollment of 1
Autor:
Amy L. Delson, Gillian L. Hirst, Amy Jo Chien, Bernhard Zimmermann, L.J. van 't Veer, Alexey Aleshin, Denise M. Wolf, Svetlana Shchegrova, Raheleh Salari, AM DeMichele, Laura J. Esserman, H. Pawar, Mark Jesus M. Magbanua, Himanshu Sethi, Antony Tin, S Asare, MC Liu, Lamorna Brown Swigart, Debu Tripathy, Maggie C. Louie, C-Hj Lin, Paul Billings, Christina Yau, H.-T. Wu
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology, vol 32, iss 2
Ann Oncol
Ann Oncol
Author(s): Magbanua, MJM; Swigart, LB; Wu, H-T; Hirst, GL; Yau, C; Wolf, DM; Tin, A; Salari, R; Shchegrova, S; Pawar, H; Delson, AL; DeMichele, A; Liu, MC; Chien, AJ; Tripathy, D; Asare, S; Lin, C-HJ; Billings, P; Aleshin, A; Sethi, H; Louie, M; Zimm
Autor:
Yen-Shen Lu, Seock-Ah Im, Marco Colleoni, Fabio Franke, Aditya Bardia, Fatima Cardoso, Nadia Harbeck, Sara Hurvitz, Louis Chow, Joohyuk Sohn, Keun Seok Lee, Saul Campos-Gomez, Rafael Villanueva Vazquez, Kyung Hae Jung, K. Govind Babu, Paul Wheatley-Price, Michelino De Laurentiis, Young-Hyuck Im, Sherko Kuemmel, Nagi El-Saghir, Ruth O'Regan, Claudia Gasch, Nadia Solovieff, Craig Wang, Yongyu Wang, Arunava Chakravartty, Yan Ji, Debu Tripathy
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 28, iss 5
Purpose: Ribociclib plus endocrine therapy (ET) demonstrated a statistically significant progression-free survival and overall survival (OS) benefit in the phase III MONALEESA-7 trial of pre-/perimenopausal patients with hormone receptor (HR)-positiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff6fc5fc3fed4998874ffed5668fb72a
https://escholarship.org/uc/item/6hf2w93b
https://escholarship.org/uc/item/6hf2w93b
Autor:
Akshara Singareeka Raghavendra, Raymond Sawaya, Fuchenchu Wang, Nuhad K. Ibrahim, Limin Hsu, Eric A. Strom, Debu Tripathy, Jing Li, Chao Gao, Dima Suki
Publikováno v:
International Journal of Cancer. 148:961-970
Outcomes of treatments for patients with breast cancer brain metastasis (BCBM) remain suboptimal, especially for systemic therapy. To evaluate the effectiveness of systemic and local therapy (surgery [S], stereotactic radiosurgery [SRS] and whole bra
Autor:
Yesim Gökmen-Polar, Lajos Pusztai, Richard D. Kennedy, Alastair M. Thompson, Priyanka Sharma, Kirsten Timms, Daniel F. Hayes, Gabriel N. Hortobagyi, Peggy L. Porter, Debu Tripathy, Hannah M. Linden, Shane R. Stecklein, Andrew K. Godwin, William E. Barlow, Sunil Badve
Publikováno v:
Cancer Research. 81:GS3-05
Introduction/Aims: DDIR signature, HRD, and stromal tumor infiltrating lymphocytes (sTIL) have each been associated with favorable outcomes in early stage TNBC. We assessed the overlap between these markers and created prognostic categories based on
Autor:
Debu Tripathy, Takeo Fujii, James P. Long, Sudpreeda Chainitikun, Toshiaki Iwase, Ruben Rodriguez-Bautista, Naoto T. Ueno
Publikováno v:
Breast Cancer Res Treat
PURPOSE: Combinations of endocrine therapy (ET) and targeted therapy (CDK4/6 or mTOR inhibitors) are standard of care for HR+/HER2- metastatic breast cancer (MBC). When ET is not effective, chemotherapy is commonly used. However, clinical outcomes of
Publikováno v:
Cancer Research. 80:P3-10
BACKGROUND: Eribulin mesylate, a non-taxane microtubule-dynamics inhibitor, is an effective chemotherapy drug for patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens. We are seeking to enhance th
Autor:
Wendy Demark-Wahnefried, Kerry S. Courneya, Christina M. Dieli-Conwright, Kyuwan Lee, Joanne E. Mortimer, Debu Tripathy
Publikováno v:
Cancer Research. 80:P1-11
Background Breast cancer survivors have approximately double the risk of mortality from cardiovascular disease than age-matched women without a cancer history. Reynolds risk score is a validated algorithm for the assessment of cardiovascular disease,